Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): Results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trial

Aoki, Takayuki; Moriya, Yoshihiro; Yoshida, Shigeaki; Shirao, Kuniaki; Ohashi, Yu; Kodaira, Susumu

doi:10.1200/jco.2004.22.90140.3524

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, one reason why adjuvant chemotherapy for SCCHN with no clinically residual tumours after definitive treatments had no impact on survival benefit has been suggested to be the lack of antitumour effect of the adjuvant chemotherapy Adjuvant chemotherapy with oral chemotherapeutic agents has not been studied in Western countries for HNSCC. Oral administration of UFT (tegafur and uracil in a 1 : 4 molar concentration) has been shown significant survival benefit in the adjuvant setting in a variety of carcinomas, for example, colorectal, gastric, lung and breast cancer (Akasu et al, 2004;Kato et al, 2004;Kinoshita et al, 2005;Noguchi et al, 2005), while 1-year administration of UFT (300 mg day À1 ) as adjuvant chemotherapy for SCCHN after curative surgical treatment significantly prevented distant metastasis with a small survival benefit (Tsukuda et al, 1994).…”

Section: Discussionmentioning

confidence: 99%

“…The fluoropyrimidine anticancer agent 5-fluorouracil (5-FU) is active in a variety of solid tumours, particularly gastric, colorectal and SCCHN. Recently, the adjuvant chemotherapy of UFT (tegafur and uracil in a 1 : 4 molar concentration), one of the oral 5-FU agents, has shown a significant survival benefit in a wide range of carcinomas (Akasu et al, 2004;Kato et al, 2004;Kinoshita et al, 2005;Noguchi et al, 2005). Furthermore, a prospective randomized trial to evaluate the efficacy of adjuvant chemotherapy in SCCHN from 67 institutions in Japan showed the 1-year administration of UFT (300 mg day À1 ) in cases receiving curative surgical treatment was clarified to prevent distant metastasis significantly with a small survival benefit compared to the outcome of the control cases receiving curative surgery without adjuvant chemotherapy of UFT (Tsukuda et al, 1994).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

et al. 2005

View full text Add to dashboard Cite

The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). Patients receiving definitive treatments were randomly assigned to either arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week administration followed by 2-week rest for 6 months. Planned treatment was given in 40% of patients in arm A and 29% in arm B. The cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.1 -69.7%) in arm A and 34.3% (95% CI: 21.1 -47.4%) in arm B, respectively (P ¼ 0.054). Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients (94.1%) in arm B (P ¼ 0.060). The incidences of diarrhoea (10 vs 28%; Po0.05) and skin toxicities (18 vs 37%; Po0.05) were significantly higher in arm B. One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI: 70.0 -92.4%); arm B 77.0% (95% CI: 65.0 -89.0%). The schedule of 2-week administration followed by 1-week rest seems to be more feasible for oral 6-month administration of S-1 in adjuvant chemotherapy of locoregionally advanced SCCHN.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Interim analysis showed statistically significant prolongation of diseasefree survival in patients who concomitantly received oral UFT compared with patients who underwent surgery alone (p = 0.0014) [20] .…”

Section: Discussionmentioning

confidence: 99%

Dihydropyrimidine Dehydrogenase Activity during Long-Term Adjuvant Treatment with Oral Uracil and Tegafur for Colorectal Cancer

Sadahiro

Suzuki²,

Maeda³

et al. 2007

Chemotherapy

View full text Add to dashboard Cite

Background: Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme for the degradation of 5-fluorouracil. The effect of long-term treatment with oral fluoropyrimidines on DPD activity has not been investigated. This study was conducted to examine changes in DPD activity in peripheral mononuclear cells (PMNC) during long-term treatment with oral uracil and tegafur (UFT) for colorectal cancer. Methods: UFT was administered for 5 consecutive days and not administered the next 2 days for 6 months after surgery. PMNC-DPD activity was measured before and 1, 2, 4 and 6 months after starting UFT administration. Results: In 70 eligible patients, there were no significant variations of PMNC-DPD activity during postoperative administration of UFT for 6 months. Grade 2 or higher adverse events were observed in significantly more patients with low DPD than with high DPD activity (p = 0.018). Conclusion: There were no significant variations of PMNC-DPD activity during the postoperative administration of UFT for 6 months. Low PMNC-DPD activity before UFT treatment was considered to be a predicting factor for toxicity.

show abstract

Chemotherapy in rectal cancer

Arnold

Siewczynski

Schmoll

2005

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC): Results of the National Surgical Adjuvant Study (NSAS)-Colorectal Cancer (CC) 01 randomized trial

Cited by 4 publications

References 0 publications

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

Dihydropyrimidine Dehydrogenase Activity during Long-Term Adjuvant Treatment with Oral Uracil and Tegafur for Colorectal Cancer

Chemotherapy in rectal cancer

Contact Info

Product

Resources

About